Maryland-based biotechnology company Novavax Inc (Nasdaq:NVAX) announced that it is starting a phase 1/2 clinical trial of its COVID-19 vaccine candidate ‘NVX?CoV2373’ in Australia.
Novavax mentioned that the first participants in a phase 1/2 clinical trial has been enrolled. This trial would be conducted in two parts- phase 1 and phase 2. The results of Phase 1 portion are anticipated in July 2020.
Moreover, phase 2 portion will be commenced promptly after successful Phase 1 outcomes.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.